FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels.
Amyloid-PET
FDG-PET
Hyperactivation
Hypermetabolism
Mild cognitive impairment
Tau-PET
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
19 10 2020
19 10 2020
Historique:
received:
15
04
2020
accepted:
05
10
2020
entrez:
20
10
2020
pubmed:
21
10
2020
medline:
25
6
2021
Statut:
epublish
Résumé
FDG-PET hypermetabolism can be observed in mild cognitive impairment (MCI), but the link to primary pathologies of Alzheimer's diseases (AD) including amyloid and tau is unclear. Using voxel-based regression, we assessed local interactions between amyloid- and tau-PET on spatially matched FDG-PET in 72 MCI patients. Control groups included cerebrospinal fluid biomarker characterized cognitively normal (CN, n = 70) and AD dementia subjects (n = 95). In MCI, significant amyloid-PET by tau-PET interactions were found in frontal, lateral temporal, and posterior parietal regions, where higher local tau-PET was associated with higher spatially corresponding FDG-PET at low levels of local amyloid-PET. FDG-PET in brain regions with a significant local amyloid- by tau-PET interaction was higher compared to that in CN and AD dementia and associated with lower episodic memory. Higher tau-PET in the presence of low amyloid-PET is associated with abnormally increased glucose metabolism that is accompanied by episodic memory impairment.
Sections du résumé
BACKGROUND
FDG-PET hypermetabolism can be observed in mild cognitive impairment (MCI), but the link to primary pathologies of Alzheimer's diseases (AD) including amyloid and tau is unclear.
METHODS
Using voxel-based regression, we assessed local interactions between amyloid- and tau-PET on spatially matched FDG-PET in 72 MCI patients. Control groups included cerebrospinal fluid biomarker characterized cognitively normal (CN, n = 70) and AD dementia subjects (n = 95).
RESULTS
In MCI, significant amyloid-PET by tau-PET interactions were found in frontal, lateral temporal, and posterior parietal regions, where higher local tau-PET was associated with higher spatially corresponding FDG-PET at low levels of local amyloid-PET. FDG-PET in brain regions with a significant local amyloid- by tau-PET interaction was higher compared to that in CN and AD dementia and associated with lower episodic memory.
CONCLUSION
Higher tau-PET in the presence of low amyloid-PET is associated with abnormally increased glucose metabolism that is accompanied by episodic memory impairment.
Identifiants
pubmed: 33076977
doi: 10.1186/s13195-020-00702-6
pii: 10.1186/s13195-020-00702-6
pmc: PMC7574434
doi:
Substances chimiques
Amyloid
0
Amyloid beta-Peptides
0
tau Proteins
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
133Références
J Alzheimers Dis. 2012;29(1):109-23
pubmed: 22214785
Neurology. 2010 Jan 19;74(3):201-9
pubmed: 20042704
J Nucl Med. 2017 Dec;58(12):1984-1990
pubmed: 28705919
Neuron. 2007 Sep 6;55(5):697-711
pubmed: 17785178
Arch Neurol. 2005 Nov;62(11):1728-33
pubmed: 16286547
JAMA. 1995 Mar 22-29;273(12):942-7
pubmed: 7884953
Ann Neurol. 2009 Aug;66(2):200-8
pubmed: 19743450
Nat Neurosci. 2016 Aug;19(8):1085-92
pubmed: 27322420
J Neurosci. 2011 Nov 30;31(48):17680-8
pubmed: 22131428
Neurology. 2005 Aug 9;65(3):404-11
pubmed: 16087905
Neurology. 2017 Mar 14;88(11):1054-1061
pubmed: 28188306
J Neuropathol Exp Neurol. 2016 Jun;75(6):482-98
pubmed: 27209644
Alzheimers Dement. 2015 Jul;11(7):757-71
pubmed: 26194311
Alzheimers Dement. 2018 Nov;14(11):1470-1481
pubmed: 29499171
Ann Neurol. 2008 Oct;64(4):388-401
pubmed: 18991338
J Neurosci. 2011 Jan 12;31(2):700-11
pubmed: 21228179
Cereb Cortex. 2012 Sep;22(9):1993-2004
pubmed: 22038908
Neurobiol Dis. 2018 Sep;117:181-188
pubmed: 29859869
Acta Neuropathol Commun. 2013 Jul 11;1:34
pubmed: 24252661
J Alzheimers Dis. 2016 Nov 19;55(2):465-471
pubmed: 27802224
Ann Neurol. 2012 Oct;72(4):578-86
pubmed: 23109153
J Neurosci. 2019 Jan 16;39(3):548-556
pubmed: 30482786
Neurobiol Aging. 2018 May;65:41-50
pubmed: 29407465
EMBO Rep. 2013 Apr;14(4):389-94
pubmed: 23412472
Brain Imaging Behav. 2012 Dec;6(4):502-16
pubmed: 22782295
Science. 1979 Aug 17;205(4407):723-5
pubmed: 462184
Acta Neuropathol Commun. 2016 Jun 13;4(1):58
pubmed: 27296779
Acta Neuropathol. 2015 May;129(5):749-56
pubmed: 25628035
Lancet Neurol. 2015 Apr;14(4):388-405
pubmed: 25792098
J Neurosci. 2017 Mar 22;37(12):3192-3201
pubmed: 28213439
J Neurosci. 2009 Nov 25;29(47):14770-8
pubmed: 19940172
Hum Brain Mapp. 2014 Jan;35(1):297-308
pubmed: 22965806
Neurobiol Aging. 2015 Feb;36(2):693-709
pubmed: 25442111
Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):447-58
pubmed: 25267349
Front Neuroinform. 2016 Jun 15;10:20
pubmed: 27378902
Neurology. 2007 Feb 13;68(7):501-8
pubmed: 17065593
Alzheimers Dement. 2018 Aug;14(8):1005-1014
pubmed: 29605222
J Neurosci. 2017 Apr 19;37(16):4323-4331
pubmed: 28314821
CNS Neurosci Ther. 2019 Jan;25(1):5-13
pubmed: 30101571
Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):E4502-9
pubmed: 24194552
Alzheimers Dement. 2019 Jan;15(1):8-16
pubmed: 30465754
Ann Neurol. 2017 Apr;81(4):583-596
pubmed: 28253546
Alzheimers Res Ther. 2014 Nov 21;6(9):82
pubmed: 25419243
Acta Neuropathol. 2014 Dec;128(6):755-66
pubmed: 25348064
Cereb Cortex. 2019 May 1;29(5):1997-2009
pubmed: 29912295
Ann Neurol. 2010 Dec;68(6):865-75
pubmed: 21194156
Nat Neurosci. 2019 Jan;22(1):57-64
pubmed: 30559471
Ann Neurol. 2017 Apr;81(4):549-559
pubmed: 28224671
Brain Commun. 2020;2(1):fcz046
pubmed: 32051933
Neuron. 2012 May 10;74(3):467-74
pubmed: 22578498
Am J Geriatr Psychiatry. 2014 Oct;22(10):961-70
pubmed: 24495404
Brain. 2016 May;139(Pt 5):1551-67
pubmed: 26962052
Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2169-81
pubmed: 18566819
Hum Brain Mapp. 1996;4(1):58-73
pubmed: 20408186